Follicular lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 27
• CD20 14
• BTK 9
• BCL-2 5
• CD22 5
• MYC 3
• EZH2 2
• PD-1 3
• PI3K 0
• PD-L1 1
• TP53 0
• CD40 0
• CD47 0
• CXCR4 0
• EGFR 0
• HDAC 0
• ABL1 0
• AKT 0
• ALK 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD30 0
• CSF1R 1
• G6PD 0
• IL-1 0
• IL-15 0
• IL-17 0
• LAG-3 0
• MEK 0
• PPAR 0
• STAT3 0
• TFEB 0
• TIGIT 1
• TIM-3 0

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R43

  Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma

  Biologica Llc· Charlotte, United States· US$385,056 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  INHIBITION OF EZH2 TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER

  University of Pennsylvania· Philadelphia, United States· US$704,044 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · F31

  Real-Time Monitoring of Nanobubble-Labeled Chimeric Antigen Receptor T cell Trafficking via Contrast-Enhanced Ultrasound

  Case Western Reserve University· Cleveland, United States· US$50,114 awarded in fiscal year 2026· until Jun 2028

• NIH NCI · K99

  Comprehensive Profiling of Tumor and Tumor Immunity for Developing Personalized Interventions for T-cell Lymphomas

  Stanford University· Stanford, United States· US$137,266 awarded in fiscal year 2026· until Jun 2028

• NIH NCI · R01

  Translating Insights in Follicular Lymphoma for Improved Diagnosis and Classification

  New York University School of Medicine· New York, United States· US$706,137 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxembourg· EU contribution €216,240· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Making patient-derived tumor organoids a reliable cancer therapy testing platform (TUMORGPLAT)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €245,490· until Dec 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in the Tissue Microenvironment

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €296,296· until Apr 2027· 2 countries

8 of 33 running projects, newest first. Listed amounts together: US$20.7m + €758.0k.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Whole Genome Sequencing 1
• Flow Cytometry 2
• Immunohistochemistry 12
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 2
• Cohort Studies 6
• Genome-Wide Association Study 4

• MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL.

  Blood Adv, Oct 2026

• Roadmap for developing MRD as an early endpoint for drug approval in lymphoma.

  Semin Hematol, Mar 2026

• Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

  J Clin Oncol, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.